Dunn, S. E., Khong, H. T., Beeram, M., Wesolowski, R., Han, H. S., Palaskas, N. J., Jayanthan, A., Olivo, M. S., Barnett, B. (2025). Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps1130